Asia-pacific Genetic Testing Market Forecast 2022-2030
KEY FINDINGS
The Asia-Pacific genetic testing market is projected to register a CAGR of 10.49% during the forecast period, 2022-2030. High population, developing economies, increasing cases of cancer, and low cost of professional services and treatments are expected to propel the market growth.
MARKET INSIGHTS
The Asia-Pacific genetic testing market growth evaluation includes the assessment of China, Thailand, Australia & New Zealand, Indonesia, South Korea, India, Japan, and Rest of Asia-Pacific. Japan is a highly developed market with AI capabilities and futuristic technology in the medical field. Moreover, prenatal testing has caught up in the Japanese market post-World War II. Also, genetic testing has grown in popularity among the geriatric population of the country.
Additionally, India is known for its immense capabilities to produce drugs and medicines. Also, India remains a popular destination for medical tourism. With the rapidly increasing population in the country, the cost of tests is reducing significantly with the rising volumes in addition to several major companies operating in the sector.
In Singapore, the Singapore Cancer Action Network (SCAN) has issued guidelines for referrals of genetic testing that serve as a guide for clinicians. There is an increasing demand for genetic testing for hereditary cancer syndromes as the population is well educated coupled with greater awareness. Hence, these factors are set to propel the Asia-Pacific genetic testing market growth during the forecast years.
COMPETITIVE INSIGHTS
Some of the important market players include Luminex Corporation, Quest Diagnostics Inc, 23&Me Inc, Illumina Inc, Roche Diagnostics Inc, etc.
Our report offerings include:
Explore key findings of the overall market
Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
Market Segmentation cater to a thorough assessment of key segments with their market estimations
Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
- 1. Research Scope & Methodology
- 1.1. Study Objectives
- 1.2. Scope Of Study
- 1.3. Methodology
- 1.4. Assumptions & Limitations
- 2. Executive Summary
- 2.1. Market Size & Estimates
- 2.2. Market Overview
- 3. Market Dynamics
- 3.1. Key Drivers
- 3.1.1. Advancements In Biotechnology
- 3.1.2. Growth In Prenatal Testing
- 3.1.3. Rise In Direct-to-consumer Genetic Testing
- 3.1.4. Genetic Testing Helps In Determining Medication Dosage
- 3.2. Key Restraints
- 3.2.1. Expensive Cost Of Treatment
- 3.2.2. Government Regulation And Legislation
- 4. Key Analytics
- 4.1. Impact Of Covid-19 On Genetic Testing Market
- 4.2. Key Market Trends
- 4.3. Porter’s Five Forces Analysis
- 4.3.1. Buyers Power
- 4.3.2. Suppliers Power
- 4.3.3. Substitution
- 4.3.4. New Entrants
- 4.3.5. Industry Rivalry
- 4.4. Opportunity Matrix
- 4.5. Vendor Landscape
- 4.6. Value Chain Analysis
- 4.7. Key Buying Criteria
- 4.8. Regulatory Framework
- 5. Market By Type
- 5.1. Prenatal And Newborn Testing
- 5.2. Diagnostic Testing
- 5.3. Predictive & Presymptomatic Testing
- 5.4. Carrier Testing
- 5.5. Pharmacogenomic Testing
- 5.6. Other Types
- 6. Market By Technology
- 6.1. Molecular Testing
- 6.2. Cytogenetic Testing
- 6.3. Biochemical Testing
- 7. Market By Application
- 7.1. Genetic Disease Diagnosis
- 7.2. Cancer Diagnosis
- 7.3. Cardiovascular Disease Diagnosis
- 7.4. Other Applications
- 8. Market By Disease
- 8.1. Cancer
- 8.2. Cystic Fibrosis
- 8.3. Huntington’s Disease
- 8.4. Sickle Cell Anaemia
- 8.5. Duchenne Muscular Dystrophy
- 8.6. Alzheimer’s Disease
- 8.7. Rare Diseases
- 8.8. Thalassemia
- 8.9. Other Diseases
- 9. Geographical Analysis
- 9.1. Asia-pacific
- 9.1.1. Market Size & Estimates
- 9.1.2. Key Growth Enablers
- 9.1.3. Key Challenges
- 9.1.4. Key Players
- 9.1.5. Country Analysis
- 9.1.5.1. China
- 9.1.5.2. Japan
- 9.1.5.3. India
- 9.1.5.4. South Korea
- 9.1.5.5. Indonesia
- 9.1.5.6. Australia & New Zealand
- 9.1.5.7. Singapore
- 9.1.5.8. Taiwan
- 9.1.5.9. Rest Of Asia-pacific
- 10. Competitive Landscape
- 10.1. Key Strategic Developments
- 10.1.1. Mergers & Acquisitions
- 10.1.2. Product Launches & Developments
- 10.1.3. Partnerships & Agreements
- 10.1.4. Business Expansions & Divestitures
- 10.2. Company Profiles
- 10.2.1. 23&Me Inc
- 10.2.2. Abbott Laboratories
- 10.2.3. Bgi Group
- 10.2.4. Bio-rad Laboratories
- 10.2.5. Csl Limited
- 10.2.6. Decode Genetics
- 10.2.7. Elitech Group
- 10.2.8. Eurofins Scientific
- 10.2.9. Illumina Inc
- 10.2.10. Luminex Corporation
- 10.2.11. Myriad Genetics Inc
- 10.2.12. Perkinelmer Inc
- 10.2.13. Qiagen
- 10.2.14. Quest Diagnostics Inc
- 10.2.15. Roche Diagnostics Inc
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook